Breathe Well Live Well
|
Array Shares Climb After Asthma Drug Shows Positive Phase 2 Results
Xconomy Array hopes ARRY-502 can become the next successful oral treatment for asthma, CEO Ron Squarer said during a conference call about the results. The market is substantial, and it has been 15 years since the FDA last approved an oral non-steroidal drug … |
View full post on asthma – Google News
REM |
Array Biopharma Inc (NASDAQ:ARRY) attains midstage triumph for asthma …
FinancialsTrend Dallas, Texas 07/24/2013 (Financialstrend) – Array Biopharma Inc (NASDAQ:ARRY) has an additional benefit on deck for a prospective affiliation. The Boulder, CO-based medicine creator has touted upbeat Stage II facts for an experimental medicine in … Biotech News Bundle: BioCryst, NeoStem, Array Biopharma , Lexicon, GTx … Biotech Top Gainers,BioCryst Pharmaceuticals,Array Biopharma,NeoStem … Biotech Stocks Amid Structural And Capital Change: BioCryst Pharmaceuticals … |
View full post on asthma – Google News
|
Array asthma drug posts good results
Boulder County Business Report Ron Squarer, chief executive of Array, noted, "With many asthma patients poorly controlled on currently available therapies, a drug targeting a novel, nonoverlapping mechanism may present an important new option for millions of patients. We are seeking … |
View full post on asthma – Google News
|
Array Biopharma's asthma drug helps lung function in study
Denver Post Boulder-based Array Biopharma Inc. said one of its drugs met the main goal of improving lung function in a mid-stage study among patients with mild to moderate persistent allergic asthma. Array shares rose 10.4 percent Tuesday, to close at $6.14 after … Array Seeks Asthma Drug Partner Following Mid-Stage Study Results Array Shares Climb After Asthma Drug Shows Positive Phase 2 Results Array BioPharma: ARRY-502 Meets Primary And Secondary Endpoints In … |
View full post on asthma – Google News
|
Array says asthma drug improves lung function in study, seeks partner for …
MedCity News (Reuters) – Array Biopharma Inc said one of its drugs met the main goal of improving lung function in a mid-stage study among patients with mild to moderate persistent allergic asthma. Array shares rose as much as 19 percent to $6.64 — their highest … |
View full post on asthma – Google News
|
Shares jump as Array BioPharma reports positive results for asthma drug
The Pharma Letter US biotech firm Array BioPharma (Nasdaq: ARRY) saw its shares jump as it announced that its drug candidate for mild to moderate persistent allergic asthma, ARRY-502, an oral CRTh2 antagonist, met all primary and secondary endpoints. The company said … |
View full post on asthma – Google News
|
Array BioPharma: ARRY-502 Meets Primary And Secondary Endpoints In …
RTT News Array BioPharma Inc. (ARRY: Quote) announced positive results from a placebo-controlled, randomized, double-blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist. ARRY-502 achieved the primary … |
View full post on asthma – Google News
|
Array asthma drug meets main goal in mid-stage study
Reuters (Reuters) – Array Biopharma Inc said one of its drugs met the main goal of improving lung function in a mid-stage study among patients with mild to moderate persistent allergic asthma. Array shares rose as much as 19 percent to $6.64 — their highest … |
View full post on asthma – Google News
|
Array Seeks Asthma Drug Partner Following Mid-Stage Study Results
TheStreet.com BOULDER, Col. (TheStreet) — An experimental pill from Array BioPharma (ARRY) improved lung function in patients who suffer from asthma brought on by allergies, according to results from a small mid-stage study announced Tuesday. Array shares rose 15 … |
View full post on asthma – Google News
|
Array Biopharma's new asthma drug meets goal of improved lung function
Denver Post Array Biopharma Inc. said Tuesday, one of its drugs met the main goal of improving lung function in a mid-stage study among patients with mild to moderate persistent allergic asthma. Array shares rose 12.7 percent, or 71 cents, to $6.27 in morning … Array BioPharma: Study Shows Asthma Candidate ARRY-502 Improves Lung … Array BioPharma scores midstage success for asthma drug Array Shares Climb After Asthma Drug Shows Positive Phase 2 Results |
View full post on asthma – Google News